QNTM Stock Analysis: Buy, Sell, or Hold?
QNTM - Quantum Biopharma Ltd. Class B Subordinate Voting Shares
$3.51
0.15 (4.46%)
▲
5d:
-10.69%
30d:
-31.31%
90d:
-20.41%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When QNTM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: QNTM is down 10.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: QNTM is down 10.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: QNTM is currently trading at $3.51, which is considered slightly low relative to its 30-day fair value range of $3.27 to $5.67.
Technical Outlook: Technically, QNTM is in a uptrend. The price is currently testing key support at $3.59. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 4.5% recently.
Market Sentiment: QNTM has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $12.28 (+249.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, QNTM is in a uptrend. The price is currently testing key support at $3.59. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 4.5% recently.
Market Sentiment: QNTM has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $12.28 (+249.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.27 -
$5.67
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.5%)
- BULLISH: Trading 249.9% below Wall St target ($12.28)
- WARNING: Recommendation downgraded due to -10.7% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$3.27 -
$5.67
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.59
Resistance Level
$7.83
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Wall Street Target
$12.28
(+249.9%)
Share & Embed Analysis
Last updated: July 02, 2026 10:46 PM ET
Data refreshes hourly during market hours. Next update: 11:46 PM
Data refreshes hourly during market hours. Next update: 11:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is QNTM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 51 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 55 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |